Progyny, Inc. (PGNY)
Market Cap | 4.10B |
Revenue (ttm) | 309.68M |
Net Income (ttm) | 3.20M |
Shares Out | 86.27M |
EPS (ttm) | -0.99 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 21 |
Last Price | $47.28 |
Previous Close | $48.58 |
Change ($) | -1.30 |
Change (%) | -2.68% |
Day's Open | 48.93 |
Day's Range | 47.20 - 48.93 |
Day's Volume | 757,030 |
52-Week Range | 16.47 - 48.93 |
This fertility stock could have serious long-term potential.
Nio, BlackBerry, Tilray, Five9 and Progyny were our top stock trades for Tuesday. Let's check out the charts after a long holiday weekend.
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United S...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United S...
Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2020 Results - Earnings Call Transcript
Progyny went public in October 2019, raising $130 million. The firm provides fertility and family planning benefit services in the United States.
Progyny (PGNY) delivered earnings and revenue surprises of 0.00% and 6.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Progyny (NASDAQ:PGNY) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 66.67% over the past year to $0.05, which ...
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United S...
Pharmacy benefits manager Progyny Inc (NASDAQ: PGNY) is trading 8.22% lower on thin volume in the pre-market session on Thursday. The company disclosed in SEC form 4 that TPG Group Holdings, w...
Researchers Studied Journey Level Analysis of Progression to Treatment Versus Drop Out in a Large Cohort of Patients with Access to a Defined Fertility Benefit Researchers Studied Journey Leve...
There are a handful of companies with no debt in the stock market, but not all of them are worth a close look. Here are seven that are.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the Unite...
Progyny provides employers with fertility benefits to help their employees build families.
Livingston Will Continue Reporting to Pete Anevski, Progyny’s President and Chief Operating Officer Livingston Will Continue Reporting to Pete Anevski, Progyny’s President and Chief Operating ...
Growth stocks have been the market's biggest winners. Amid valuation concerns, these 10 stocks still have the potential for 100%-plus gains.
Progyny, Inc's (PGNY) CEO David Schlanger on Q2 2020 Results - Earnings Call Transcript
Reports Second Quarter Revenue of $64.6 MillionPatient Return to Treatment Faster Than ExpectedIssues Revenue Guidance of $323.0 to $340.0 Million for Full Year 2020, Reflecting Growth of 41% ...
NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United...
Progyny: In Its Third Trimester And Poised For Healthy Growth
Progyny, Inc. (PGNY) CEO David Schlanger on Q1 2020 Results - Earnings Call Transcript
Company Well-Positioned to Successfully Manage COVID-Related Impacts Reports 72% Increase in First Quarter Revenue to $81.0 MillionReports $12.1 Million in Quarterly Operating Cash Flow, Addin...
Progyny reports earnings after the close today as fertility clinics postpone procedures due to the coronavirus pandemic. The post Progyny Reports Earnings Late As Coronavirus Delays Fertility ...
Nasdaq Partners with Progyny to Bring Comprehensive and Inclusive Fertility and Family Building Benefits to its US Employees Nasdaq Partners with Progyny to Bring Comprehensive and Inclusive F...
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the Unite...
Progyny, Inc. (PGNY) CEO David Schlanger on Q4 2019 Results - Earnings Call Transcript
Progyny earnings for Q4 are due after the close as the fertility benefits manager begins its selling season. The post Progyny Earnings Are Due Late; Start Of Selling Season Will Clarify Compet...
Since entering into the public market last October, shares of Progyny Inc. (NASDAQ:PGNY), a company specializing in providing fertility and family benefits solutions for U.S.
Progyny: A Growth Stock With A Unique Value Proposition
Here are five recent IPOs near buy points: XP, Dynatrace, Progyny, Datadog and Bill.com. Three are already turning profits.
Dow Backs Off 29,000 Level After Weak Jobs Report
Major stock indexes weakened late Friday, ending with mild losses in light volume.
Progyny and Zoom Video stocks are zooming.
Progyny (NASDAQ: PGNY), is a benefits management company that specializes in fertility and family building benefits solutions. The company’s stock is up 90% since its listing in late October, ...
IPO stocks Dynatrace, Datadog, Progyny, Ping Identity and Starbucks rival Luckin Coffee are all near buy points. But handle IPOs with care.
Stocks Rip Higher On Strong Jobs Report
News of better than expected job growth in November fueled another rally on Wall Street Friday.
Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2019 Results - Earnings Call Transcript
Fertility benefits manager and recent IPO Progyny reports third-quarter earnings after the close as the stock sets up in a base.
Salesforce.com, Dollar General, Marvell Technology, Synopsys and hot IPO Progyny are near buy points with earnings on tap. The post Salesforce, Dollar General, Progyny Lead 5 Stocks Near Buys...
Stocks Fall In Short Day; Progyny, Adobe, Salesforce Near Buy Points
Stocks Fall In Short Day; Progyny, Adobe, Salesforce Near Buy Points.
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United...
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United...
According to these filters, the following are significant trades from company insiders this month.
NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Progyny, Inc., a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today ...
Progyny Inc., the fertility and family building benefits company that serves US employers like Google, Apple, announced its Initial Public Offering of 10,000,000 shares at a price of $13.00 pe...
Progyny Inc., the fertility and family building benefits company that serves US employers like Google, Apple, announced its Initial Public Offering of 10,000,000 shares at a price of $13.00 pe...
About PGNY
Progyny, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clie... [Read more...]
Industry Health Information Services | IPO Date Oct 25, 2019 |
CEO David J. Schlanger | Employees 167 |
Stock Exchange NASDAQ | Ticker Symbol PGNY |
Analyst Forecasts
According to 4 analysts, the average rating for Progyny stock is "Buy." The 12-month stock price forecast is 47.75, which is an increase of 0.99% from the latest price.